Skip to main content
. 2017 Sep 4;4(4):402–408. doi: 10.1002/ehf2.12204

Figure 3.

Figure 3

(A) Effect of angiotensin‐converting enzyme inhibitors (ACE‐Is) and angiotensin receptor blockers (RCBs) on all‐cause mortality in patients with heart failure with preserved ejection fraction. (B) Effect of ACE‐Is on all‐cause mortality in patients with heart failure with preserved ejection fraction. CI, confidence interval; RCT, randomized clinical trial; RR, relative risk.